Stocks · News reference
Pentair Stock Plunge follows Pool destocking, weaker Q2 estimates and deep 2026 guidance cuts alongside a CFO transition
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Financial education platform Funkled has partnered with advice technology provider Focus to integrate digital client engagement tools directly into its free learning platform. Starting August 1st, Funkled will launch a 30-day content programme with daily modules and podcasts covering financial topics, aiming to address the UK's advice gap where only 8.7% of adults take financial advice.
Invesco senior managing director Jeffrey H. Kupor sold 26,002 shares valued at $702,314 on July 2, 2026, but this was a non-discretionary tax withholding event related to restricted stock unit vesting, not a voluntary sale. The transaction is insignificant for investors to monitor. More importantly, Invesco posted its 11th consecutive quarter of positive organic growth with $22 billion in net inflows, $2.2 trillion in assets under management, and raised its dividend while authorizing a $1 billion buyback.
Kaplan Fox has filed securities class action lawsuits against UWM Holdings Corporation, Taboola.com Ltd., and Pentair plc on behalf of investors who suffered losses during specified periods. The primary case against UWM Holdings alleges the company failed to disclose that it had deviated from its traditional strategy by over-hedging mortgage servicing rights in anticipation of the Two Harbors transaction, resulting in a $603.2 million derivative loss and a 34.78% stock price decline on August 6, 2026.
Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against Capricor Therapeutics, Pentair plc, and Bloom Energy Corporation on behalf of investors who suffered losses. The primary case involves Capricor, where the FDA released briefing documents revealing that the company made undisclosed changes to its statistical analysis plan for a drug application, resulting in a 64% stock price drop on July 27, 2026.